Perrigo acquires fifth largest player within the European OTC market for $4.5 billion
DUBLIN — Perrigo and Omega Pharma, one of the largest OTC healthcare companies in Europe, on Thursday announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for $4.5 billion; this is comprised of the purchase of Omega's equity for $3.1 billion and the assumption of $1.4 billion in debt. The transaction, funded through a combination of cash, debt, and equity will enhance Perrigo's OTC product offering and expand its distribution through Omega's established platform, the companies stated.
"The combination of these two great companies accelerates Perrigo's international growth strategy, substantially diversifies our business streams and establishes a durable leadership position in the European OTC marketplace," stated Perrigo chairman, president and CEO Joseph Papa. "We believe this strategic transaction will enhance shareholder value by further strengthening our industry-leading revenue and cash flow growth profile and by expanding market opportunities. Omega brings a leading OTC product portfolio, European capabilities and a highly experienced management team to support Perrigo's continued growth," he said. "Our strong financial performance and operational structure have enabled the continued growth and globalization of our business model with Ireland as our gateway for this expansion. Together, our combined company will have an even larger product portfolio, broader geographic reach, and enhanced scale."
"Since our founding in 1987, we have been relentlessly executing our pharmacist-focused growth strategy across Europe. We have successfully developed a top OTC product portfolio and a leading European commercial infrastructure," commented Marc Coucke, Omega CEO. "This is an exciting time in the history of our company. My continued ownership investment demonstrates my confidence in the potential for the combined company. Together, we will have a substantially broader product portfolio with established global platforms and commercial channels to better serve our customers and patients."
Omega generated approximately $1.6 billion of revenue during the twelve months ended Sept. 30, 2014, making it the fifth largest player within the European OTC market and the largest or second largest player in four individual European markets. Omega owns many leading cough & cold, skincare, pain relief, weight management and gastrointestinal treatment brands, among its portfolio of roughly 2,000 products. Omega has a strong presence in both established and emerging growth economies. Including product acquisitions, Omega has delivered compound annual revenue growth of approximately 10% over the last five years. Headquartered in Belgium, Omega also offers geographic diversification with a commercial presence in 35 countries.
Perrigo has also identified opportunities for incremental for top-line growth, driven by leveraging many of Perrigo's 3,000 complementary products across its core segments in OTC, VMS, and animal health into Omega's European commercial network.
The proposed transaction, which has been unanimously approved by the respective boards of directors of Perrigo and Omega, is subject to the satisfaction of closing conditions, including customary regulatory approvals. The transaction is expected to close in the first quarter of calendar year 2015.
J.P. Morgan Securities and Barclays are serving as financial advisers to Perrigo, and Freshfields Bruckhaus Deringer is serving as legal adviser. Morgan Stanley is serving as financial adviser to the sellers (Waterland Private Fund V CV, Marc Coucke and co-investors) in connection with this transaction, and Allen & Overy is serving as legal adviser.
LaCorium Health refreshes graphics on flagship product, Flexitol Heel Balm
WESTFIELD, N.J. — LaCorium Health, the maker of the Flexitol line of therapeutic skincare products, recently refreshed the package graphics on its flagship product, Flexitol Heel Balm for rough, dry and cracked feet.
The winning design was chosen after research showed that the new package was more visible on store shelves and better communicated the benefits of Flexitol, while staying true to the brand’s heritage.
In addition, the new package design highlights the results of a new clinical study demonstrating that most consumers will experience visible results in just one day when using Flexitol Heel Balm as directed. The new carton graphics started rolling out in late October, and all sizes will ship bearing the new look by the first quarter of 2015.
Provider tool initiates patient conversations on weight released by STOP Obesity Alliance
BOSTON — The Strategies to Overcome and Prevent (STOP) Obesity Alliance on Wednesday released a tool for healthcare providers that offers guidance and suggestions on how to initiate conversations with adult patients about weight and health. "Why Weight? A Guide to Discussing Obesity & Health With Your Patients" is a unique tool designed to help providers build a safe and trusting environment with patients to facilitate open, productive conversations about weight.
Weight is a complex and sensitive issue, and conversations surrounding the topic can be challenging. Because obesity and overweight affect two-thirds of Americans, healthcare providers increasingly are being called on to support their patients in matters dealing with weight.
Many providers have concerns about how to begin discussing weight in ways that are empowering and nonjudgmental. The tool discusses potential scenarios providers may face and suggests ways to approach the conversation.
“Research has shown that behavioral and medical treatment can be effective, but improvised and uninformed discussions may stigmatize, shame or fail to engage patients, to the detriment of the provider-patient relationship and patient outcomes,” said STOP Obesity Alliance director William Dietz. “This tool offers providers a unique and much-needed resource that can help them to facilitate conversations about weight.”
In addition to skills for building a safe, trusting environment with patients and facilitating productive conversations about weight, the guide also includes practical information on coding and patient accommodation.
STOP developed the guide using a comprehensive process that included conducting an audit of available research on provider-patient communication and consultation with a range of experts from obesity practice and research, primary care practice, nutrition education, women’s health, minority health and the patient community to offer insight based on their expertise and to guide development of the tool.
“We are thrilled to have taken part in the process to develop this tool and think it does an excellent job of responding to a real need among providers for resources to initiate these difficult conversations,” said Wendy Nickel, director, Center for Patient Partnership in Healthcare for the American College of Physicians. “It is a well-informed and valuable resource.”
Loading Post Please Wait...